618446-06-3

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
1,8-Naphthyridin-2(1H)-one, 7-amino-3,4-dihydro-4,4-dimethylis utilized as a chemical entity in pharmaceutical research and drug development for its distinctive naphthyridine ring structure and the presence of an amino group, which may contribute to its potential biological activity. 1,8-Naphthyridin-2(1H)-one, 7-amino-3,4-dihydro-4,4-dimethyl-'s specific molecular features could make it a candidate for the design of new therapeutic agents, targeting various diseases and conditions.
Further research is essential to understand the compound's pharmacological properties, including its mechanism of action, safety profile, and efficacy in treating specific medical conditions. The exploration of its potential uses in different therapeutic areas, such as oncology, infectious diseases, or neurological disorders, could pave the way for the development of novel drugs with improved efficacy and safety profiles.

Upstream product

• 141-86-6 2.6-diaminopyridine 
• 3350-78-5 3,3-Dimethylacryloyl chloride 
• 846035-54-9 3-Methyl-but-3-enoic acid (6-amino-pyridin-2-yl)-amide 

Downstream Products

• 1303587-03-2 4,4-dimethyl-N-(3-methylpyridin-4-yl)-7-(3-(trifluoromethyl)phenyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide 
• 1303586-95-9 4,4-dimethyl-N-(pyridin-4-yl)-7-(3-(trifluoromethyl)phenyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide 
• 1303588-35-3 4,4-dimethyl-7-(3-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydro-1,8-naphthyridine 

Relevant academic research and scientific papers

BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

ISOQUINOLINE [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR TREATMENT OF SCHIZOPHRENIA

Compounds of formula 1 (1) are disclosed, wherein G is as shown in formula (i): (i). A of formula 1 is -(CH2)nCO-, wherein n is 4 or 5, and one or two of the carbon atoms of A can be substituted as described in the specification. D, Z, Q, X, Y, K, J, R1, R4 through R7, and R9 through R11 of formulae 1 and (i) are defined in the specification. Also provided are descriptions of processes for preparing compounds of formula 1, intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.

SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE

The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.

Substituted alkylamine derivatives and methods of use

Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.